Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Nature Protocols
|
September 4, 2021
An LC-MS/MS assay and complementary web-based tool to quantify and predict compound accumulation in E. coli
Emily J Geddes, Zhong Li, Paul J Hergenrother
ACS Infectious Diseases
|
November 18, 2023
Cell-Based Assay to Determine Type 3 Secretion System Translocon Assembly in <i>Pseudomonas aeruginosa</i> Using Split Luciferase
Hanling Guo, Emily J Geddes, Timothy J Opperman, et al.
ACS Infectious Diseases
|
November 24, 2020
Compound Uptake into <i>E. coli</i> Can Be Facilitated by <i>N</i>-Alkyl Guanidiniums and Pyridiniums
Sarah J Perlmutter, Emily J Geddes, Bryon S Drown, et al.
Journal of the American Chemical Society
|
May 21, 2020
Gram-Negative Antibiotic Active Through Inhibition of an Essential Riboswitch
Stephen E Motika, Rebecca J Ulrich, Emily J Geddes, et al.
Nature Microbiology
|
November 20, 2019
Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens
Erica N Parker, Bryon S Drown, Emily J Geddes, et al.
Chemical Science
|
December 15, 2021
Rationalizing the generation of broad spectrum antibiotics with the addition of a positive charge
Nandan Haloi, Archit Kumar Vasan, Emily J Geddes, et al.
Nature
|
November 22, 2023
Porin-independent accumulation in Pseudomonas enables antibiotic discovery
Emily J Geddes, Morgan K Gugger, Alfredo Garcia, et al.
ACS Infectious Diseases
|
May 13, 2026
Large-Scale Chemical-Genetic Interaction Profiling Identifies a Small-Molecule Inhibitor of <i>Mycobacterium tuberculosis</i> Polyketide Synthase 13
James E Gomez, Matthew Y Solomon, Diana K Hunt, et al.
ACS Central Science
|
August 29, 2022
An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections
Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
ACS Central Science
|
October 3, 2022
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections"
Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Nature Protocols
|
September 4, 2021
An LC-MS/MS assay and complementary web-based tool to quantify and predict compound accumulation in E. coli
Emily J Geddes, Zhong Li, Paul J Hergenrother
ACS Infectious Diseases
|
November 18, 2023
Cell-Based Assay to Determine Type 3 Secretion System Translocon Assembly in <i>Pseudomonas aeruginosa</i> Using Split Luciferase
Hanling Guo, Emily J Geddes, Timothy J Opperman, et al.
ACS Infectious Diseases
|
November 24, 2020
Compound Uptake into <i>E. coli</i> Can Be Facilitated by <i>N</i>-Alkyl Guanidiniums and Pyridiniums
Sarah J Perlmutter, Emily J Geddes, Bryon S Drown, et al.
Journal of the American Chemical Society
|
May 21, 2020
Gram-Negative Antibiotic Active Through Inhibition of an Essential Riboswitch
Stephen E Motika, Rebecca J Ulrich, Emily J Geddes, et al.
Nature Microbiology
|
November 20, 2019
Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens
Erica N Parker, Bryon S Drown, Emily J Geddes, et al.
Chemical Science
|
December 15, 2021
Rationalizing the generation of broad spectrum antibiotics with the addition of a positive charge
Nandan Haloi, Archit Kumar Vasan, Emily J Geddes, et al.
Nature
|
November 22, 2023
Porin-independent accumulation in Pseudomonas enables antibiotic discovery
Emily J Geddes, Morgan K Gugger, Alfredo Garcia, et al.
ACS Infectious Diseases
|
May 13, 2026
Large-Scale Chemical-Genetic Interaction Profiling Identifies a Small-Molecule Inhibitor of <i>Mycobacterium tuberculosis</i> Polyketide Synthase 13
James E Gomez, Matthew Y Solomon, Diana K Hunt, et al.
ACS Central Science
|
August 29, 2022
An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections
Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
ACS Central Science
|
October 3, 2022
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections"
Erica N Parker, Brett N Cain, Behnoush Hajian, et al.
Page
of 1